



(11) **EP 3 890 703 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(48) Corrigendum issued on:  
**11.10.2023 Bulletin 2023/41**

(45) Date of publication and mention  
of the grant of the patent:  
**06.09.2023 Bulletin 2023/36**

(21) Application number: **19821281.3**

(22) Date of filing: **04.12.2019**

(51) International Patent Classification (IPC):  
**A61K 9/00** <sup>(2006.01)</sup> **A61K 9/08** <sup>(2006.01)</sup>  
**A61K 9/19** <sup>(2006.01)</sup> **A61K 47/10** <sup>(2017.01)</sup>  
**A61K 47/12** <sup>(2006.01)</sup> **A61K 47/18** <sup>(2017.01)</sup>  
**A61K 47/26** <sup>(2006.01)</sup> **A61K 31/5377** <sup>(2006.01)</sup>  
**A61K 47/32** <sup>(2006.01)</sup> **A61K 47/38** <sup>(2006.01)</sup>

(52) Cooperative Patent Classification (CPC):  
**A61K 9/0019; A61K 9/08; A61K 9/19;**  
**A61K 31/5377; A61K 47/10; A61K 47/12;**  
**A61K 47/183; A61K 47/26; A61K 47/32;**  
**A61K 47/38**

(86) International application number:  
**PCT/IB2019/060437**

(87) International publication number:  
**WO 2020/115676 (11.06.2020 Gazette 2020/24)**

(54) **NOVEL PHARMACEUTICAL FORMULATION COMPRISING A STING MODULATOR**

NEUARTIGE PHARMAZEUTISCHE FORMULIERUNG BEINHALTEND EINEN STING MODULATOR

NOUVELLE FORMULATION PHARMACEUTIQUE COMPRENANT UN MODULATEUR DU STING

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(30) Priority: **06.12.2018 US 201862776102 P**

(43) Date of publication of application:  
**13.10.2021 Bulletin 2021/41**

(73) Proprietor: **GlaxoSmithKline Intellectual Property**  
**Development Ltd**  
**Stevenage SG1 2NY (GB)**

(72) Inventors:  
• **DHANIKULA, Anand Babu**  
**Collegeville, Pennsylvania 19426 (US)**

• **MCQUEEN, Lisa**  
**Collegeville, Pennsylvania 19426 (US)**

(74) Representative: **Knight, Lucie Viktoria et al**  
**GlaxoSmithKline**  
**Global Patents (CN925.1)**  
**980 Great West Road**  
**Brentford, Middlesex TW8 9GS (GB)**

(56) References cited:  
**WO-A1-2017/175147**

• **SERAJUDDIN ET AL: "Salt formation to improve**  
**drug solubility", ADVANCED DRUG DELIVERY**  
**REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 59,**  
**no. 7, 24 August 2007 (2007-08-24), pages**  
**603-616, XP022211982, ISSN: 0169-409X, DOI:**  
**10.1016/J.ADDR.2007.05.010**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).